Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BIO Bio-Rad Laboratories Inc
- Stocks
- Healthcare
- NYSE: BIO
Price (delayed)
$238.68
Market cap
$6.5B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$76.07
Enterprise value
$7.34B
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley,
Highlights
The debt has declined by 2.2% year-on-year
The equity has contracted by 26% YoY
The net income fell by 17% QoQ
Key stats
What are the main financial stats of BIO
Market
Valuations
Earnings
Shares outstanding
27.21M
Market cap
$6.5B
Enterprise value
$7.34B
Price to earnings (P/E)
N/A
Price to book (P/B)
1
Price to sales (P/S)
2.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.89
Revenue
$2.54B
Gross profit
$1.36B
Operating income
$247.99M
Net income
-$2.16B
EBIT
-$2.7B
EBITDA
-$2.7B
Free cash flow
$355.56M
Per share
Balance sheet
Liquidity
EPS
-$76.07
EPS diluted
-$76.1
Free cash flow per share
$12.73
Book value per share
$238.46
Revenue per share
$90.94
TBVPS
$315.53
Total assets
$9.53B
Total liabilities
$2.85B
Debt
$1.37B
Equity
$6.68B
Working capital
$2.53B
Debt to equity
0.21
Current ratio
5.99
Quick ratio
4.12
Net debt/EBITDA
-0.31
Margins
Efficiency
Dividend
EBITDA margin
-106.3%
Gross margin
53.5%
Net margin
-85.2%
Operating margin
9.8%
Return on assets
-22.1%
Return on equity
-31.5%
Return on invested capital
-28.4%
Return on capital employed
-29.9%
Return on sales
-106.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BIO stock price
How has the Bio-Rad Laboratories stock price performed over time
Intraday
-0.97%
1 week
0.99%
1 month
-4.21%
1 year
-13.93%
YTD
-27.34%
QTD
-2%
Financial performance
How have Bio-Rad Laboratories's revenue and profit performed over time
Revenue
$2.54B
Gross profit
$1.36B
Operating income
$247.99M
Net income
-$2.16B
Gross margin
53.5%
Net margin
-85.2%
BIO's operating income is down by 23% year-on-year and by 8% since the previous quarter
BIO's operating margin is down by 20% year-on-year and by 7% since the previous quarter
The net margin has declined by 18% since the previous quarter
The net income fell by 17% QoQ
Price vs fundamentals
How does BIO's price correlate with its fundamentals
Growth
What is Bio-Rad Laboratories's growth rate over time
Valuation
What is Bio-Rad Laboratories stock price valuation
P/E
N/A
P/B
1
P/S
2.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.89
The EPS has decreased by 16% from the previous quarter
BIO's P/B is 29% below its 5-year quarterly average of 1.4 and 17% below its last 4 quarters average of 1.2
The equity has contracted by 26% YoY
The stock's price to sales (P/S) is 48% less than its 5-year quarterly average of 5.0 and 18% less than its last 4 quarters average of 3.2
The revenue has contracted by 2.5% YoY
Efficiency
How efficient is Bio-Rad Laboratories business performance
The company's return on invested capital fell by 28% QoQ
The ROE is down by 28% since the previous quarter
Bio-Rad Laboratories's ROA has decreased by 26% from the previous quarter
The ROS has decreased by 19% from the previous quarter
Dividends
What is BIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BIO.
Financial health
How did Bio-Rad Laboratories financials performed over time
The total assets has declined by 24% year-on-year
BIO's total liabilities is down by 20% year-on-year
The debt is 79% smaller than the equity
Bio-Rad Laboratories's debt to equity has increased by 40% YoY
The equity has contracted by 26% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.